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Treatment of type 2 diabetes mellitus has ex-
panded from treating blood glucose in the diag-
nosed diabetic patient with a view to reducing di-
abetic complications to the prevention of new
cases and early detection of the disease through
frequent screening. Recent trials investigating
lifestyle changes and various antidiabetic oral
agents have been shown to delay or possibly even
prevent the onset of type 2 diabetes mellitus [1–5].
At present, however, there are no clear guidelines
for the prevention of type 2 diabetes. Concerning
the screening of asymptomatic subjects, the Amer-
ican Diabetes Assocation recommends screening
by fasting glucose at 3-year intervals in all persons
aged 45 or over [6]. Where risk factors are present
screening at a younger age and at more frequent
intervals is recommended. However, the evidence
is scarce for either recommendation and may not
be cost-effective [7]. Furthermore, in the setting of
prevention of complications the focus has been
widened from exclusive attention to blood glucose
management to include control of blood pressure
and lipids and prevention of platelet aggregation
with aspirin. In addition, weight reduction, life-
style modification and smoking cessation have
gained increasing importance. Thus, regular re-
view of blood pressure, weight, nutritional habits
and physical activity, as well as measurement of
glycated haemoglobin (HbA1c) every 3–6 months,
are receiving stronger emphasis. In the absence of
specific problems, annual dilated eye examina-
tions, annual comprehensive foot examinations
and checking for foot pulses and carotid bruits as
well as yearly measurement of serum lipids and uri-
nary albumin excretion are recommended. Guide-
lines for treatment goals, particularly for preven-
tion of cardiovascular disease, differ slightly be-
tween the various professional organisations [6, 8]
and are summarised in Table 1. 
Current guidelines for treatment of type 2 di-
abetes mellitus include disease prevention and the
control of blood pressure and lipids in addition to
blood glucose management. However, physician
compliance with treatment guidelines is relatively
poor. In any given year, HbA1c and blood lipids are
measured only in about half of patients and are
below target in even less, while blood pressure is
frequently measured but controlled in less than
50%. Some reasons for this unsatisfactory situa-
tion are providers’ beliefs, frustration and lack of
knowledge, patient barriers and the fact that the
guidelines are not easy to access and implement.
Patient non-adherence can be changed by im-
proving education, perception, motivation and
self-management. Strategies for improving disease
management are discussed.
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Summary
Treatment guidelines and change of the treatment goal paradigm
How well do physicians manage their patients?
Although standards of care for diabetes have
been widely publicised since the late 1980s, prac-
titioners have been hesitant to adopt the recom-
mended guidelines [6, 9]. The St. Vincent’s Dec-
laration Initiative in 1989 set the goal of reducing
diabetic complications by at least one third. More
than 10 years later, the Cost of Diabetes in Europe-
Type II (CODE-2) study measured the current
quality of care for type 2 diabetes patients in Eu-
rope. 
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Blood glucose control
During the 6 months of the CODE-2 study,
HbA1c was tested in only 64% of the study popu-
lation; 31% achieved blood glucose control at or
below 6.5% and 45% at or below 7.5% [10]. Gly-
cated haemoglobin measurements were not docu-
mented in 50% of Italian patients in the care of
general practitioners, in part due to rare patient
visits [11]. On the other hand, a large national sur-
vey from Sweden revealed that, in 1999, 48% of
the type 2 diabetic patients had HbA1c at or below
6.5% [12]. 
Blood pressure
Studies reviewing charts generally show good
adherence to blood pressure measurements
[13–16], but not to blood pressure control. In the
CODE-2 study blood pressure was within the tar-
get ranges set by the European Diabetes Policy
Group in only 53% [10]. Data from the Swedish
National Survey even showed blood pressure at or
below 140/85 in only 36% of patients [17]. More-
over, optimum blood pressure control appears to
be even more difficult to achieve, since in two
European surveys less than 10% had a blood pres-
sure below 130/85 [17, 18].
Lipids
Even more surprisingly, LDL-cholesterol was
measured in only 27% of patients in the European
CODE-2 study [10]. In a recent Swedish study,
LDL-cholesterol values were reported in 89% of
the diabetic patients, but were below target in only
36% of these subjects [19].
Subgroup analyses underline the benefits of
blood pressure and lipid control for prevention of
diabetes-related endpoints [20–22]. Thus, lower-
ing HbA1c in middle-aged type 2 diabetics from 
7.9 to 7% prevents 5 out of 100 diabetes-related
endpoints over the next 10 years, while lowering
blood pressure from approximately 155/85 to
140/80 prevents 16 out of 100 endpoints [23]. In
general, we appear to neglect management of
lipids and blood pressure in particular, even
though these concomitant risk factors are at least
as important and can often be treated with less time
and effort than blood glucose control. 
Weight and nutrition
Weight is usually recorded in the majority of
subjects, while documentation of height is fairly
rare [24]. Hence it is often impossible to calculate
BMI. Diet recommendations, concerning carbo-
hydrate allowances and fat restriction in particu-
lar, are frequently omitted in daily practice. A
nutritional survey throughout Europe found that
patients had a low adherence rate to the recom-
mendations, with too high a proportion of fat in-
take, especially saturated fat, and too low an intake
of carbohydrates [25]. 
Diabetic complications 
and preventive measures
Measures to prevent diabetic complications
are often either neglected or underrecorded. In
any year, primary care physicians document foot
examinations in 8–52% of their diabetics and di-
lated eye examinations in 22–60%, and measure
urinary protein or albumin in 33–91% of their pa-
tients [13–16, 19, 26, 27]. Structured annual dia-
betes check-ups are documented in 15%. Smoking
habits, alcohol use and influenza and pneumococ-
cal vaccines are recorded in a minority of patients
[16, 24]. Referrals to a dietician are documented in
one third of patients or less, and to diabetes nurses
in 1–3% [15, 24], though such referrals are prob-
ably more frequent than documented. One study
reviewed charts of dieticians and diabetes nurses
and interviewed patients. They showed that about
75% of type 2 diabetic patients taking insulin had
received diet instruction at least once and had at
least one formal session with a diabetes education
team, whereas this was true only of about half of
type 2 diabetic patients not receiving insulin [28]. 
Are specialists doing any better? One report
found no meaningful differences in health out-
comes, including blood glucose control, in patients
with diabetes who were treated by specialists or
generalists [29], but several studies have shown
better blood glucose control in patients treated by
specialists [18, 30–32]. One study comprehen-
sively assessed different risk factors and preventive
measures in the context of routine endocrinology
practices. In all type 2 diabetic patients HbA1c av-
eraged 6.9%, while HbA1c was ≤8% in 87%.
Blood pressure levels averaged 133/72 mm Hg.
Over a 12-month period, lipid profiles were meas-
ured in 70%, with an average LDL-cholesterol
value of 2.61 mmol/l, 74% of patients received di-
lated eye examinations and 55% had urine albu-
min screening [30].
HbA1c LDL-cholesterol Blood pressure
European Diabetes Policy Group (EDPG) ≤6.5% <3 mmol/l <140/85 mm Hg
Swiss Society of Endocrinology and Diabetology (SGED) <7% <2.6* mmol/l <135/85 mm Hg
* Newly revised by the Swiss Working Group for Lipids and Atherosclerosis (AGLA)
Table 1
Guidelines for treat-
ment goals as recom-
mended by different
professional organi-
sations.
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Physician compliance
One reason for the lack of compliance with
guidelines might be lack of knowledge of, or belief
in, more recent guidelines, as most of them are
based on relatively new data possibly unknown to
the physician. Providers’ beliefs and attitudes
influence their adherence. In many cases type 2
diabetes is still considered a non-serious disease, or
there is frustration concerning the effectiveness of
the treatment if complications occur despite good
quality therapy [33]. Blood glucose control seems
harder to achieve than other conditions. The lack
of clear symptoms or their immediate relief by
treatment, frequent fluctuations in blood glucose
levels, frustrating efforts to achieve lifestyle
changes and prescribing of treatment that is also
physically painful, such as finger sticks for glucose
monitoring or insulin injections, render blood glu-
cose control a difficult and tedious task for many
physicians [9]. Lack of trained support personnel
in and outside the office, lack of public support 
and potential financial concerns are additional bar-
riers to good control [9, 34]. There is often inde-
cision whether to start insulin, despite chronic hy-
perglycaemia, partly due to final attempts at
changes in diet, patient unwillingness, fear of hy-
poglycaemia and weight gain, and, most impor-
tantly, physicians’ unfamiliarity with the different
insulin regimens and the new injection devices
(pens). In particular, physicians are uncertain when
to start insulin and which and how much insulin
they should use. Workshops addressing these is-
sues are currently ongoing in many European
countries, including Switzerland.
On the other hand, physicians may have valid
reasons for not complying with evidence-based
guidelines, e.g. patient non-adherence, geriatric
study populations and advanced comorbidities. In
addition, the complexity and bulk of current guide-
lines for diabetic care in themselves inhibit their
implementation within the time and money con-
straints of modern medicine. The effectiveness of
physicians is enhanced by furthering their knowl-
edge of diabetes [35] and in particular by influenc-
ing their attitudes [9]. In addition, providers could
be trained to improve their communication skills
further and to promote behavioural change [9].
Staff training and use of educational material for
patients are helpful aids [34]. A team approach in
conjunction with a diabetes nurse and a dietician,
focusing on acceptance of illness and patient edu-
cation, or involvement of expert consultants, can
lighten the load for physicians and improve dia-
betes outcomes [36]. A case-control study has re-
ported that patients who did not receive any form
of educational intervention had a fourfold in-
creased risk of developing complications analysed
by multivariate logistic regression analysis [37].
Patient barriers should be identified, and action
plans with realistic objectives and documented
physician and patient goals should be established.
Guidelines have the best chance of changing physi-
cian behaviour when they are adapted and devel-
oped by the clinicians for whom they are intended,
on the basis of national or international guidelines,
and implemented via patient-specific reminders
during consultations [38]. Furthermore, specific
time for comprehensive annual check-ups, longer
appointment times for patients with chronic dis-
eases, provision of automated reminder systems
and tools such as flowsheets or health care check-
lists have all been shown to improve diabetes care
[6, 9, 39]. Use of non-physician providers to per-
form some examinations, such as blood pressure
measurements or foot examinations, to refer pa-
tients to the ophthalmologist or order laboratory
studies, appears to benefit patient care [16, 36].
Patient barriers
Patient barriers to good management are non-
acceptance and absence of symptoms, divergent
cultural concepts, chronicity of the disease, spe-
cific expectations and beliefs, comorbid conditions
and psychiatric disease [35, 40]. In addition, the
consequences of non-adherence are delayed. Fac-
tors diminishing adherence are confusion regard-
ing the drug regimen, fear of side effects, the pro-
gressive nature of the disease, and costs [35, 40].
Adherence declines with increasing number and
frequency of the drugs prescribed and frequent
changes in drug regimen [40, 41]. Patients follow
treatment regimens more readily if they involve
medication rather than lifestyle changes [9]. Pa-
tient satisfaction is generally increased in practices
where physicians view their relation to patients as
a partnership, and if the patients are kept informed
and involved in medical decisions [42]. However,
in one study increased satisfaction alone did not in-
fluence blood pressure or metabolic control, thus
showing the additional importance of disease man-
agement [42]. On the other hand, giving patients
more responsibility and involving them actively in
their own care produces improvement in all car-
diovascular risk factors and even microvascular
complications [43]. 
Patient education is a fundamental prerequi-
site for diabetes self-management [44, 45]. It is im-
portant that both physicians and diabetes educa-
tors provide unequivocal and consistent informa-
tion, with a view to modifying patient perceptions,
attitudes and behaviour [46]. This is a necessity in
designing and implementing a successful diabetes
self-care plan with individual goals [44]. Blood
glucose monitoring may serve as an additional tool
in improving motivation and adherence. To fur-
ther encourage self-care, some countries, such as
Switzerland, have a patient diabetes passport
showing the most recent findings for physical ex-
amination and laboratory values, together with the
respective goals. 
Why are physicians doing so poorly and what could be improved?
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Health education was previously aimed at per-
suading the public to adopt a specific recommen-
dation or persuading patients to comply with treat-
ment. This has now changed, and education has
shifted towards enabling persons to make in-
formed choices concerning health-related behav-
ior [23]. Empowerment or self-management of pa-
tients can be achieved only if priority is given to
enhancing education, motivation and skilled use of
modern techniques in a structured team approach. 
Conclusions
In summary, diabetes is a silent, but serious
disease. It is of the utmost importance for physi-
cians to improve their own adherence and quality
assessment, not only to improve glucose manage-
ment but to tighten lipid and blood pressure con-
trol. Lifestyle changes represent the first step in
management, and often a team approach is neces-
sary. Even patients whose blood glucose control is
good should have access to formal diabetes educa-
tion, to train them in the use of technical aids and
increase their knowledge of the disease and their
therapy. They should be accompanied through the
different stages of disease acceptance which form
the basis for current and future treatment adher-
ence [45]. In cases of poor metabolic control de-
spite adequate medical management, or intoler-
ance to lifestyle changes or therapy, patient barri-
ers should be more thoroughly addressed. If fast-
ing blood glucose or HbA1c rise above 8 mmol/l
or 7% respectively and the patient is already 
taking oral antidiabetic drugs, insulin should be
started. Antihypertensives and statins should be
used to attain the specific treatment goals. This,
along with patient motivation and empowerment,
is necessary to achieve a healthier life for all dia-
betics.
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